Movement Alert｜BEONE MEDICINES Intraday Decline 3.1%, Innovative Drug Sector Pressured by Peer Trial Setback

Market Focus

Yesterday

On October 9, BEONE MEDICINES fell 3.1% in regular trading, trading at HK$206.4 with turnover of HK$192 million.

The decline came as the broader innovative drug sector faced selling pressure after peer Aolis's core product failed a global Phase III trial, raising concerns over pipeline execution and weighing on sentiment across Hong Kong-listed biotech names. Despite BEONE MEDICINES' strong interim results and multiple buy ratings from institutions, recent selling by founding shareholder Wang Xiaodong in September and changes in JPMorgan's position continued to temper short-term investor confidence.

BEONE MEDICINES AG (formerly BeiGene Ltd) is a global oncology company developing novel therapies for cancer, with a portfolio spanning hematology and solid tumors, including products such as Brukinsa, Tevimbra, and Pamiparib.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hkg.itiger.com/news/1158175534"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158175534\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158175534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-09 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158175534","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Intraday Decline 3.1%, Innovative Drug Sector Pressured by Peer Trial Setback","media":"Market Focus","content":"<p><p>On October 9, BEONE MEDICINES fell 3.1% in regular trading, trading at HK$206.4 with turnover of HK$192 million.</p><p>The decline came as the broader innovative drug sector faced selling pressure after peer Aolis's core product failed a global Phase III trial, raising concerns over pipeline execution and weighing on sentiment across Hong Kong-listed biotech names. Despite BEONE MEDICINES' strong interim results and multiple buy ratings from institutions, recent selling by founding shareholder Wang Xiaodong in September and changes in JPMorgan's position continued to temper short-term investor confidence.</p><p>BEONE MEDICINES AG (formerly BeiGene Ltd) is a global oncology company developing novel therapies for cancer, with a portfolio spanning hematology and solid tumors, including products such as Brukinsa, Tevimbra, and Pamiparib.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Intraday Decline 3.1%, Innovative Drug Sector Pressured by Peer Trial Setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Intraday Decline 3.1%, Innovative Drug Sector Pressured by Peer Trial Setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-09 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 9, BEONE MEDICINES fell 3.1% in regular trading, trading at HK$206.4 with turnover of HK$192 million.</p><p>The decline came as the broader innovative drug sector faced selling pressure after peer Aolis's core product failed a global Phase III trial, raising concerns over pipeline execution and weighing on sentiment across Hong Kong-listed biotech names. Despite BEONE MEDICINES' strong interim results and multiple buy ratings from institutions, recent selling by founding shareholder Wang Xiaodong in September and changes in JPMorgan's position continued to temper short-term investor confidence.</p><p>BEONE MEDICINES AG (formerly BeiGene Ltd) is a global oncology company developing novel therapies for cancer, with a portfolio spanning hematology and solid tumors, including products such as Brukinsa, Tevimbra, and Pamiparib.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1158175534","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158175534","pubTimestamp":1791513122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 9, BEONE MEDICINES fell 3.1% in regular trading, trading at HK$206.4 with turnover of HK$192 million.The decline came as the broader innovative drug sector faced selling pressure after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势提醒|BEONE MEDICINES盘中下跌3.1%，创新药板块受同行试验挫折压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On October 9, BEONE MEDICINES fell 3.1% in regular trading, trading at HK$206.4 with turnover of HK$192 million.The decline came as the broader innovative drug sector faced selling pressure after peer Aolis's core product failed a global Phase III trial, raising concerns over pipeline execution and weighing on sentiment across Hong Kong-listed biotech names. Despite BEONE MEDICINES' strong interim results and multiple buy ratings from institutions, recent selling by founding shareholder Wang Xiaodong in September and changes in JPMorgan's position continued to temper short-term investor confidence.BEONE MEDICINES AG (formerly BeiGene Ltd) is a global oncology company developing novel therapies for cancer, with a portfolio spanning hematology and solid tumors, including products such as Brukinsa, Tevimbra, and Pamiparib.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}